Article
Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.
Thoracic cancer - 1 Aug 2022
Hosomi Yukio, Seto Takashi, Nishio Makoto, Goto Koichi, Yamamoto Noboru, Okamoto Isamu, Tajima Kosei, Kajihara Yusuke, Yamamoto Nobuyuki
Abstract excerpt
BACKGROUND: In the phase II JO25567 study (JapicCTI-111390), erlotinib plus bevacizumab demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor receptor mutation-positive (EGFR+) non-small cell lung cancer (NSCLC). Here, we present an exploratory analysis investigating the impact of baseline pleural/pericardial effusion (PPE) on patient outcomes. METHODS: Patients with stage...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.